Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Alzheimer's Disease Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments - Research and Markets

Research and Markets
Posted on: 03 Aug 17

The "Alzheimer's Disease Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" report has been added to Research and Markets' offering.

Pipeline Overview

Alzheimer's disease is a progressive brain disorder that gradually destroys thinking skills and memory, and ultimately the capability to carry out the basic tasks. Alzheimer's disease is presently ranked as the third leading cause of death in the aging population, after heart disease and cancer.

Alzheimer's is the most common form of dementia among elder adults. Dementia is the loss of behavioral abilities and cognitive functioning which results in interference with a person's daily life and activities and can range from severe to the mild stage. As the disease progresses, protein formation take place in the brain to form structures called 'tangles' and 'plaques'.

This results in the loss of networks between nerve cells and ultimately leads to the death of nerve cells and damage to brain tissue. Lack of some important chemical messengers has also been observed in patients suffering from Alzheimer's disease.

These chemical messengers communicate by sending signals around the brain. When there is a lack of these messengers, the signals are not transmitted efficiently.

Alzheimer's is an intricate disease and it is not possible that any therapy or one drug can successfully treat it. Current approaches include helping people to maintain mental function, manage behavioral symptoms and slow or delay the symptoms of disease.

The marketed drugs are available to reduce symptoms and improve quality of life fall under cholinesterase inhibitors class and include Donepezil, Alantamine, Rivastigmine and Tacrine.

Key Topics Covered:

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

5. Alzheimer'S Disease Pipeline Analysis By Phase (2017)

6 Competitive Landscape

7 Company Profiles

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/tpt98h/alzheimers

View source version on businesswire.com: http://www.businesswire.com/news/home/20170803005807/en/

Business Wire
www.businesswire.com

Last updated on: 03/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.